Blocking the P2X7 receptor cut inflammatory signaling in human brain tissue in the lab

What the research found

Study (human cells and surgical brain tissue, not a patient trial). ScienceDaily carried the University of Birmingham account on 7 October 2026. Jamie Cowley, Nicholas M. Barnes, and colleagues report in Brain (2026; 149(10):3614; doi 10.1093/brain/awag068). They studied the P2X7 receptor in live human brain-cell cultures and in slices taken during neurosurgery. The receptor promoted release of cytokines, including IL-1 beta. A specific blocker cut that inflammatory response in the tissue. They also turned blood monocytes into microglia-like cells, because microglia taken out of the brain lose their usual character. The same block interfered with signals from those cells as they were damaged. Barnes said existing drugs that hit this receptor might be studied again for brain inflammation, and that the next step would be trials in neurodegenerative disease or traumatic brain injury, where no drug is established for this purpose. The release names Alzheimer's, Parkinson's, multiple sclerosis, depression, and schizophrenia as conditions where inflammation is discussed. It does not report a human treatment result, a dose, or a sex or age split. Educational notes. This is not a medicine to start.

Evidence level: Lab study. Results in animals or cells often don't carry over to people.

Read the original at University of Birmingham / Brain